Checkpoint Inhibitor Combo Effective for RCC [News in Brief]

Nivolumab plus ipilimumab increases progression-free survival in high- and intermediate-risk patients.

from Cancer via ola Kala on Inoreader http://ift.tt/2hvhWkR
via IFTTT